Organon (MEX:OGN) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:OGN Organon & Co MEX:OGN
58 GF Score
Price MXN229.00
GF Value MXN246.64
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Organon Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

MEX:OGN
58GF Score
Organon & Co MEX:OGN
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Organon (MEX:OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of MXN229.00 is trading 7.2% below its estimated GF Value™ of MXN246.64. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for MEX:OGN:

  • Interest Received:
  • GF Value™: MXN246.64 vs. price of MXN229.00 (7.2% below fair value)
  • GF Score™: 58/100 with 10 warning signs

No single metric tells the full story. See the MEX:OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
58GF Score

Get the complete analysis for MEX:OGN

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN229.00
Price
MXN246.64
GF Value